Analyst Research Report Snapshot

Title:

OREXO - STEPS TO GROW ZUBSOLV SALES

Price:

$10.00

Provider:

Edison Investment Research

Date:

07 May 2014

Pages:

7

Type:

AcrobatPDF

Companies referenced:

ORX.ST

Available for Immediate Download
Summary:

Orexo is focused on initiatives to drive stepwise sales growth of Zubsolv during 2014. Zubsolv Q114 prescription volumes grew 145% over Q413 and further improvement of managed care coverage and execution in the lifecycle management programme should see continued increases in prescriptions. Previously communicated reimbursement improvements (UnitedHealth Group and OptumRx) and the salesforce reorganisation should start to have a greater impact in H214.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.